Should I buy or sell Syneos Health stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares. View SYNH analyst ratings or view top-rated stocks .

What is Syneos Health's stock price target for 2024?

4 Wall Street analysts have issued 12-month price targets for Syneos Health's shares. Their SYNH share price targets range from $43.00 to $43.00. On average, they predict the company's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price. View analysts price targets for SYNH or view top-rated stocks among Wall Street analysts .

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. The business earned $1.35 billion during the quarter, compared to analysts' expectations of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 8.63% and a net margin of 1.31%. The company's revenue was up 22.7% on a year-over-year basis. During the same quarter last year, the business earned $0.93 earnings per share.

What ETFs hold Syneos Health's stock?

ETFs with the largest weight of Syneos Health (NASDAQ:SYNH) stock in their portfolio include First Trust Health Care AlphaDEX Fund (FXH) and iShares Biotechnology ETF (IBB) . Invesco Nasdaq Biotechnology ETF (IBBQ) .

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com . Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA) , Pfizer (PFE) , Block (SQ) , Advanced Micro Devices (AMD) , Boeing (BA) , Alibaba Group (BABA) , ICON Public (ICLR) , Netflix (NFLX) , AbbVie (ABBV) and Intel (INTC) .

NASDAQ:SYNH

Syneos Health (SYNH) Stock Price, News & Analysis

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Free SYNH Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $42.97
▼
$42.99
50-Day Range: $42.48
▼
$42.98
52-Week Range: $22.89
▼
$52.23

Volume: 7.39 million shs
Average Volume: 1.92 million shs
Market Capitalization: $4.46 billion

P/E Ratio: 62.29
Dividend Yield: N/A
Price Target: $43.00

Stock Analysis

Get Syneos Health alerts:

Syneos Health MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 0.0% Upside
$43.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: -1.00
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.50 out of 5 stars

Medical Sector

872nd out of 918 stocks

Diagnostics & Research Industry

1st out of 1 stocks

1.0

Analyst's Opinion

Consensus Rating
Syneos Health has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Syneos Health has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for SYNH.

0.0

Dividend Strength

Dividend Yield
Syneos Health does not currently pay a dividend.
Dividend Growth
Syneos Health does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Syneos Health has received a 70.43% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physical health", "Clinical research services for mental health", and "Management consulting for medical technology industry" products. See details.
Environmental Sustainability
The Environmental Impact score for Syneos Health is -1.00.

0.6

News and Social Media Coverage

Search Interest
1 people have searched for SYNH on MarketBeat in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Syneos Health insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.34% of the stock of Syneos Health is held by insiders.
Percentage Held by Institutions
91.16% of the stock of Syneos Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Syneos Health is 62.29, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 139.49.
Price to Earnings Ratio vs. Sector
The P/E ratio of Syneos Health is 62.29, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 207.50.
Price to Book Value per Share Ratio
Syneos Health has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

About Syneos Health Stock (NASDAQ:SYNH)

Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina. As of September 28, 2023, Syneos Health, Inc. was taken private.

Ad Stansberry Research

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

SYNH Stock News Headlines

February 28, 2024 | bizjournals.com

Syneos Health cancels hiring goals linked to Morrisville HQ

January 12, 2024 | bizjournals.com

People to Watch in 2024: Syneos Health CEO Colin Shannon

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

January 9, 2024 | finance.yahoo.com

Syneos Health Releases 2024 Dealmakers' Intentions Survey

January 4, 2024 | markets.businessinsider.com

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

December 29, 2023 | bizjournals.com

2023 Year in Review: Syneos Health seeks turnaround after $7B deal to go private

December 20, 2023 | finance.yahoo.com

Syneos Health Releases 2024 Health Trends

October 3, 2023 | tmcnet.com

Syneos Health Appoints Colin Shannon as Chief Executive Officer

April 19, 2024 | Stansberry Research (Ad)

Strange new buyer driving up gold

One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

October 3, 2023 | markets.businessinsider.com

Syneos Health Appoints Colin Shannon To Succeed Michelle Keefe As CEO

October 2, 2023 | seekingalpha.com

SYNH Syneos Health, Inc.

September 28, 2023 | finance.yahoo.com

Syneos Health execs in line for huge payouts with $7B buyout

September 28, 2023 | finance.yahoo.com

Syneos Health Closes Transaction with Private Investment Firms

September 27, 2023 | finanznachrichten.de

S&P Dow Jones Indices: Civitas Resources Set to Join S&P MidCap 400; Hayward Holdings to Join S&P SmallCap 600

September 26, 2023 | finance.yahoo.com

Syneos Health Names Terttu Haring President, Clinical Sites & Patients

September 25, 2023 | stockhouse.com

Syneos Deadline Alert

September 23, 2023 | prnewswire.com

SYNEOS 72 HOUR DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Syneos To Contact Him Directly To Discuss Their Options

September 23, 2023 | businesswire.com

SYNEOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact ...

September 23, 2023 | businesswire.com

SYNEOS DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Syneos Health, Inc. and Encourages Investors to Contact the Firm

September 22, 2023 | benzinga.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc. (SYNH)

September 18, 2023 | finance.yahoo.com

Here’s Why ClearBridge Investments Small Cap Strategy Sold Syneos Health (SYNH)

September 14, 2023 | stockhouse.com

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Syneos Health, Inc. with Losses of $100,000 to Contact the Firm

September 13, 2023 | businesswire.com

Final Deadline Approaching for Syneos Health, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Syneos Health, Inc. (SYNH) Investors of September 25, 2023 Lead ...

September 13, 2023 | finance.yahoo.com

Syneos Health (SYNH) Declares Strategic Partnership With Oracle

September 12, 2023 | finanznachrichten.de

Syneos Health, Inc.: Syneos Health and Oracle to Expand Relationship to Accelerate Patient Recruitment & Advance Health Equity

September 11, 2023 | benzinga.com

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Syneos Health, Inc. (SYNH) Investors of a Class Action Lawsuit and Upcoming Deadline

September 10, 2023 | prnewswire.com

Syneos Health, Inc. (SYNH) Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds SYNH Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

See More Headlines

Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostics & Research
Sub-Industry: N/A
Current Symbol: NASDAQ:SYNH
CUSIP: N/A
CIK: 1610950
Web: www.syneoshealth.com
Phone: (919) 876-9300
Fax: 919-876-9360
Employees: 28,768
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $43.00
High Stock Price Target: $43.00
Low Stock Price Target: $43.00
Potential Upside/Downside: +0.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.69
Trailing P/E Ratio: 62.29
Forward P/E Ratio: 15.41
P/E Growth: N/A
Net Income: $266.50 million
Net Margins: 1.31%
Pretax Margin: 1.53%
Return on Equity: 8.63%
Return on Assets: 3.66%

Debt

Debt-to-Equity Ratio: 0.77
Current Ratio: 1.20
Quick Ratio: 1.20

Sales & Book Value

Annual Sales: $5.39 billion
Price / Sales: 0.83
Cash Flow: $6.72 per share
Price / Cash Flow: 6.40
Book Value: $33.96 per share
Price / Book: 1.27

Miscellaneous

Outstanding Shares: 103,720,000
Free Float: 103,366,000
Market Cap: $4.46 billion
Optionable: Optionable
Beta: 1.58

5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

Ms. Michelle Keefe (Age 56)
CEO & Director
Comp: $876.28k
Mr. Michael Lee Brooks (Age 49)
Chief Operating Officer
Comp: $702.11k
Mr. Jonathan Olefson Esq. (Age 47)
Gen. Counsel & Corp. Sec.
Comp: $526.13k
Mr. Christian Tucat MBA (Age 53)
Chief Bus. Officer
Comp: $517.29k
Mr. Jason M. Meggs (Age 47)
Consultant
Comp: $624.83k
Mr. Michael J. Bonello (Age 53)
Chief Financial Officer
Ms. Donna Hildebrand Kralowetz (Age 52)
Sr. VP of Fin. & Chief Accounting Officer
Mr. Baba Shetty
Pres of Technology & Data Solutions
Dr. Judith Ng-Cashin M.D. (Age 54)
Chief Scientific Officer
Mr. Larry A. Pickett Jr.
Chief Information & Digital Officer

Key Competitors

View All Competitors

SYNH Stock Analysis - Frequently Asked Questions

Should I buy or sell Syneos Health stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares.
View SYNH analyst ratings or view top-rated stocks.
What is Syneos Health's stock price target for 2024?: 4 Wall Street analysts have issued 12-month price targets for Syneos Health's shares. Their SYNH share price targets range from $43.00 to $43.00. On average, they predict the company's stock price to reach $43.00 in the next twelve months. This suggests a possible upside of 0.0% from the stock's current price.
View analysts price targets for SYNH or view top-rated stocks among Wall Street analysts.
How were Syneos Health's earnings last quarter?: Syneos Health, Inc. (NASDAQ:SYNH) posted its quarterly earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.05. The business earned $1.35 billion during the quarter, compared to analysts' expectations of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 8.63% and a net margin of 1.31%. The company's revenue was up 22.7% on a year-over-year basis. During the same quarter last year, the business earned $0.93 earnings per share.
What ETFs hold Syneos Health's stock?: ETFs with the largest weight of Syneos Health (NASDAQ:SYNH) stock in their portfolio include First Trust Health Care AlphaDEX Fund (FXH) and iShares Biotechnology ETF (IBB).Invesco Nasdaq Biotechnology ETF (IBBQ).

What is Alistair Macdonald's approval rating as Syneos Health's CEO?: 322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.
What other stocks do shareholders of Syneos Health own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

This page (NASDAQ:SYNH) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Syneos Health (SYNH) Stock Price, News & Analysis

Syneos Health MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

Search Interest

Company Ownership

Earnings and Valuation

About Syneos Health Stock (NASDAQ:SYNH)

SYNH Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

SYNH Stock Analysis - Frequently Asked Questions

Overall MarketRank^™